Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models
- Equal contributors
1 Modelling and Economics Unit, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
2 Health Economics, GlaxoSmithKline Biologicals, Avenue Fleming 20 B-1300, Wavre, Belgium
3 Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, Merck & Co., Inc., UG1C-60, PO Box 1000, North Wales, PA 19454-1099, USA
4 Medical Technology Assessment Sector, Ministry of Health, Ben Tbai 2, San Simone, Jerusalem, Israel
5 Harvard School of Public Health, Department of Health Policy and Management, Center for Health Decision Science, Boston, MA, USA
6 Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Tiwanon Road, Nonthaburi 11000, Thailand
7 Health Economics Unit, School of Public Health & Family Medicine, University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa
8 Initiative for Vaccine Research, World Health Organization, 20 Avenue Appia, 1211 Geneva, Switzerland
BMC Medicine 2011, 9:54 doi:10.1186/1741-7015-9-54Published: 12 May 2011
Additional file 1:
Literature review search strategy. Search strategy used for the literature review of economic evaluations of human papillomavirus (HPV) vaccination.
Format: DOC Size: 42KB Download file
This file can be viewed with: Microsoft Word Viewer
Additional file 2:
Standardised data set and data sources used to inform it. Details on the standardised data sets for the hypothetical low-income and middle-income countries, as well as the data sources used to inform it.
Format: DOCX Size: 102KB Download file
Additional file 3:
Articles on economic evaluations of human papillomavirus (HPV) vaccination. Articles identified as economic evaluations of HPV vaccination during the literature search published before February 2010.
Format: XLS Size: 41KB Download file
This file can be viewed with: Microsoft Excel Viewer